MARKET

BTAI

BTAI

BIOXCEL THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.08
-0.66
-2.47%
Pre Market: 26.08 0 0.00% 07:11 07/30 EDT
OPEN
26.97
PREV CLOSE
26.74
HIGH
27.17
LOW
25.27
VOLUME
6
TURNOVER
--
52 WEEK HIGH
67.74
52 WEEK LOW
23.79
MARKET CAP
724.67M
P/E (TTM)
-6.4090
1D
5D
1M
3M
1Y
5Y
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will...
GlobeNewswire · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Acutus Medical (NASDAQ:AFIB) stock increased by 9.61% to $16.3 during Tuesday's after-market session. The market value of their outstanding shares is at $548.0 million.
Benzinga · 2d ago
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 2d ago
Hookipa Shares Move Higher Following Circulation Of TipRanks Article '3 "Strong Buy" Stocks Trading at Rock-Bottom Prices'; BioXcel, Ascendis Shares Also Mentioned
https://www.tipranks.com/news/article/3-strong-buy-stocks-trading-at-rock-bottom-prices-2
Benzinga · 3d ago
Stocks That Hit 52-Week Lows On Monday
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 3d ago
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genui...
GlobeNewswire · 07/19 11:30
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BTAI. Analyze the recent business situations of BIOXCEL THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BTAI stock price target is 100.45 with a high estimate of 145.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 143
Institutional Holdings: 11.02M
% Owned: 39.67%
Shares Outstanding: 27.79M
TypeInstitutionsShares
Increased
51
1.33M
New
18
364.67K
Decreased
33
2.25M
Sold Out
19
702.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Peter Mueller
President/Chief Executive Officer/Director
Vimal Mehta
Chief Financial Officer/Senior Vice President
Richard Steinhart
Executive Vice President
William Kane
Senior Vice President/Chief Scientific Officer
Frank Yocca
Senior Vice President/Secretary
Javier Rodriguez
Senior Vice President
Reina Benabou
Senior Vice President
Vincent O'Neill
Other/Director
Krishnan Nandabalan
Independent Director
June Bray
Independent Director
Sandeep Laumas
Independent Director
Michal Votruba
No Data
About BTAI
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Webull offers kinds of BioXcel Therapeutics Inc stock information, including NASDAQ:BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.